News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?
23 Jun 2026
byNatalia Reoutova
ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.
23 Jun 2026







